Acumen pharmaceuticals to participate in stifel 2023 virtual cns days

Charlottesville, va. and carmel, ind., march 22, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat at the stifel 2023 virtual cns days on wednesday, march 29, 2023 at 12:30 p.m. et. the live webcast may be accessed under the investors tab on www.acumenpharm.com and will be archived for 14 days.
ABOS Ratings Summary
ABOS Quant Ranking